tbuckley/cabot-search huggingface dataset:
The influence of metabolic syndrome on prostate cancer risk detection and its aggressiveness.
Authors: Rafael Morales, Cristina Suarez, Jordi Ropero, Isaac Nunez, Jacques Planas, Jose Placer, Claudia María Valverde, Xavier Maldonado, Juan Morote, Joan Carles
Journal: Journal of Clinical Oncology (2012)

226 Background: Metabolic syndrome (MS) is a frequent pathological condition that increase cardiovascular risk and mortality. MS is frequently diagnosed in adult men who are at risk of prostate cancer (PC). Some studies have postulated a relationship between MS and overall oncogenesis, however no information exist in relation to PC. The objective of this study was to analyze the impact of MS on PC detection risk and PC aggressiveness. Methods: A group of 2408 men were consecutively subjected to prostate biopsy for cause, PSA &gt;4 ng/mL (64.4%), abnormal DRE (9%) or both (26.6%). Median PSA was 7.0 ng/mL (0.7-1279) and median age 68 years (46–86). MS was evaluated according to the ATPIII criteria (three or more conditions: waist circumference &gt;102 cm, triglyceride level &gt;150 mg/dL, high density lipoprotein level &lt;40 mg/dL, fasting glucosa level &gt;110 ng/dL and blood pressure &gt;130/85 mmHg. Men on lipid-lowering medications, hypoglicemiants and antihypertensives were classified as positive for the respective criterion. We took at least 10 cores in PB, plus 1 to 8 additional cores depending on age and prostate volume according to a modified Vienna’s nomogram. Overall PC detection rate was 35.2% and high grade (HG) rate (Gleason score &gt;7) 28.3%. Binary logistic regression and contingence analysis were performed and odds ratios (OR) calculated to analyze the strength of relationships. Results: The overall prevalence of MS was 61.5% (1480/2408). Multivariate analysis showed that MS was not an independent predictor of PC however MS was an independent predictor of HGPC. The rate of PC was 34.3% in men with MS (508 of 1480) and 36.6% in men without MS (340/928), p=0.255. OR: 0.904 (95%CI 0.762-1.073). The rate of HGPC was 33.1% among the PCs detected in men with MS and 21.2% among the PCs detected in men without MS, p &lt;0.001, OR 1.839 (95%IC 1.337-2.531). Conclusions: MS does not seem to increase the risk of prostate cancer detection in men subjected to PB for cause. However, we have detected an increase of the aggressiveness among PCs detected in men with MS.
Patterns of Infectious Morbidity in Patients with Waldenström’s Macroglobulinaemia/Lymphoplasmacytic Lymphoma: A Population-Based Study
Authors: Sigrun Helga Lund, Malin Hultcrantz, Lynn Goldin, Ola Landgren, Magnus Björkholm, Ingemar Turesson, Sigurdur Y Kristinsson
Journal: Blood (2014)
Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition.
Authors: Chris Verslype, Hannah van Malenstein, Jeroen Dekervel, Petra Windmolders, Louis Libbrecht, Rudy van Eijsden, Frederik Nevens, Jos van Pelt
Journal: Journal of Clinical Oncology (2012)

216 Background: Sorafenib, a multi tyrosine kinase inhibitor, is the first line treatment in patients with advanced hepatocellular carcinoma (HCC). It leads to a survival benefit but treatment with sorafenib is hampered by two phenomena: patients can develop important side-effects and eventually all patients show progression. We aimed to determine the effects of long-term exposure to sorafenib and its withdrawal in vitro. Methods: We developed sorafenib resistant liver cancer cell lines (HepG2, WRL-68 and Huh-7) by slowly increasing sorafenib concentrations. XTT- and BrdU-assay were used to study the effect of sorafenib withdrawal on proliferation and metabolism. Morphological changes were examined with immuocytochemistry, gene expression changes with RT-PCR and the invasive potential with matrigel invasion chambers. Microarray was performed on resistant HepG2 cells. Results: HepG2 cells (6µM), WRL-68 cells (6µM) and Huh-7 cells (5µM) became resistant to sorafenib. Resistance was confirmed with a shift of the IC 50 to ±16µM and ongoing phosphorylation of ERK during sorafenib exposure. All three resistant cell types showed significant increased proliferation and metabolic activity after withdrawal of sorafenib. The HepG2 resistant cells have undergone an epithelial to mesenchymal transition (EMT) with loss of E-cadherin and high expression of vimentin. The cells that displayed EMT became spindle shaped and were highly invasive. Furthermore, gene expression profiling confirmed EMT changes in a large set of EMT-related genes. Considering drug metabolism, the HepG2 sorafenib resistant cells showed a downregulation of UDP glucuronosyltransferases (UGT) and cytochromes P450, such as CYP3A4. There was a strong downregulation of different ABC-transporters, although breast cancer resistance protein (ABCG2) was upregulated. Conclusions: Long-term treatment with sorafenib can lead to the development of resistant cells, even with an aggressive phenotype because the cells can undergo EMT. Furthermore we demonstrated that abrogation of treatment leads to rebound growth, suggesting the importance of aggressive management of side-effects.
Prospective Evaluation of Chromosomal Breakages in Hemophiliac Children after Radioisotope Synovectomy with Yttrium90 and Rhenium186.
Authors: Kaan Kavakli, Ozgur Cogulu, Semih Aydogdu, Hayal Ozkilic, Burak Durmaz, Ozgur Kirbiyik, Ferda Ozkinay, Can Balkan, Deniz Yilmaz Karapinar, Yilmaz Ay, Mehmet Akin
Journal: Blood (2008)
Resident Shift Handoff Strategies in US Internal Medicine Residency Programs
Authors: Charlie M. Wray, Saima Chaudhry, Amber Pincavage, Rachel Miller, Linda DeCherrie, Karin Ouchida, Vineet M. Arora
Journal: JAMA (2016)

This survey study of US internal medicine program directors characterizes resident shift handoff strategies, education about handoffs, and the directors’ satisfaction with the process at their institution.
Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure.
Authors: Terence W. Friedlander, Vivian K. Weinberg, Alex Yeung, James Burke, Donald L. Lamm, James M. McKiernan, John J. Nemunaitis, Joe Stephenson, Eric Jay Small, Lawrence Fong, Maxwell V. Meng
Journal: Journal of Clinical Oncology (2012)

271 Background: Loss of retinoblastoma (Rb) tumor suppressor activity occurs commonly in bladder cancer and leads to upregulation of the E2F-1 transcription factor. CG0070 is a replication competent oncolytic adenovirus genetically modified to express GMCSF under control of the human E2F-1 promoter. Updated results from a phase I/II study of CG0070 in patients with recurrent superficial bladder cancer (T1, Ta, Tcis) after BCG treatment are presented here. Methods: The V-0046 phase I/II study previously reported the safety and evidence of efficacy of single and multiple doses of intravesical CG0070. Efficacy was determined using quarterly cystoscopy, biopsy, and/or urine cytology. Tumor Rb status was assessed immunohistochemically in 18 tumors. Results: 35 patients were treated with either a single dose (n=13) of CG0070 ranging from 1x10 12 to 3x10 13 viral particles (vp) or with weekly x 6 (n=9) or every 4 week x 3 doses (n=13) ranging from 1x10 12 to 1x10 13 vp per dose. Only one dose limiting toxicity, grade 3 lymphopenia in an every 4 week patient, was observed. The most common adverse events regardless of schedule were flu-like illness, dysuria, hematuria, bladder spasm, and nocturia. Urine GMCSF was detectable in 94% of patients and 58% of patients in the single dose cohort had an increase in CG0070 levels suggesting in-vivo viral replication. The CR rate in the single dose cohort was 23% (3/13), and 64% (14/22) in the multi-dose cohorts. Median follow up for all responders is 9.1 months. Of all responders, 11 recurred with a remission duration ranging from 3.0 - 33.4 months and 6 patients, all in the multiple dose cohorts, remain in remission as of last follow-up with a remission duration ranging from 3.3 – 38.2 months. Phosphorylated (inactive) Rb was detected in 13 of the 18 (72%) patients evaluated. Nine of these 13 patients (70%) had a CR. All patients (5/5, 100%) with known phosphorylated Rb treated in the weekly cohort experienced a CR. Conclusions: CG0070 was well tolerated with minimal local and systemic toxicities. Complete responses were more frequently observed in the multiple-dose cohorts, including durable CRs in patients with phosphorylated Rb. Further study in Rb inactivated tumors is warranted.
2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial
Authors: Douglas W. Sborov, Misty Lamprecht, Don Benson, Karen Tackett, Yvonne A Efebera, Rosko E Ashley, Steven M. Devine, Ming Poi, Mitch A. Phelps, Craig C Hofmeister
Journal: Blood (2014)
The Function of AML1 (RUNX1) C-Deletion Mutant in Hematopoietic Stem/Progenitor Cells.
Authors: Yusuke Satoh, Itaru Matsumura, Sachiko Ezoe, Hirokazu Tanaka, Takafumi Yokota, Jun Ishikawa, Kenji Oritani, Yuzuru Kanakura
Journal: Blood (2005)
A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).
Authors: Sergio Cortelazzo, Stefano Luminari, Monica Bellei, Maurizio Martelli, Umberto Vitolo, Luigi Rigacci, Achille Ambrosetti, Enrico Pogliani, Teodoro Chisesi, Giorgio Rossi, Andrea Rossi, Alessandro Rambaldi, Tiziano Barbui, Maura Brugiatelli, Massimo Federico
Journal: Blood (2004)
Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML)
Authors: Maria E Figueroa, Sanne Lugthart, Yushan Li, Claudia Erpelinck-Verschueren, Paul J Christos, Madhu Mazumdar, Bob Löwenberg, John Greally, Peter JM Valk, Ruud Delwel, Ari Melnick
Journal: Blood (2008)
Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study
Authors: Soham D. Puvvada, Daniel O. Persky, Lora Inclan, Jonathan H. Schatz, Ellen M Chase, Jose Guillen, D Roe, Thomas P. Miller
Journal: Blood (2013)
Association of Specific Dietary Fats With Mortality
Authors: Uffe Ravnskov, Harumi Okuyama, Zoë Harcombe
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Evidence review ordered by government backs minimum alcohol pricing
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Pressure is growing on the UK government to change its mind and approve a minimum price for a unit of alcohol in England after a comprehensive evidence review commissioned by Public Health England backed the policy.

After the report was published on Friday 2 December,1 43 organisations and experts sent a letter to the chancellor of the exchequer, Philip Hammond, calling on him to implement measures such as a minimum unit price for alcohol and increased taxes on high strength white cider, to tackle the burden of alcohol on people, the NHS, and public services.2

The new report sets out the range of existing evidence on the positive effect that a minimum price on alcohol can have in reducing the prevalence of drinking. Such a policy has been adopted by the Scottish government but not yet introduced there because of repeated legal challenges from the alcohol industry that …
Decreased Acute but Not Chronic Graft Versus Host Disease (GVHD) after Allogeneic (ALLO) Hematopoietic Stem Cell Transplant (HSCT) from Matched Sibling Donors (MRD) Using Peripheral Blood Progenitor Cells (PBPC) Mobilized with Filgastrim (GCSF) Plus Dexamethasone (DEX).
Authors: Sameer Gupta, Arabella B. Tilden, William P. Vaughan, Donna E. Salzman, Lawrence S. Lamb, Rhonda O. Katz, Matthew H. Carabasi
Journal: Blood (2004)
TORAVA trial: Lessons from this trial in the two control arms, sunitinib and bevacizumab in combination with interferon.
Authors: B. J. Escudier, D. Perol, C. Ferlay, G. Gravis, C. Chevreau, R. Delva, J. Bay, L. Geoffrois, E. Blanc, S. Negrier
Journal: Journal of Clinical Oncology (2011)

315 Background: The TORAVA trial, reported at ASCO 2010, was a randomized phase II study aimed to determine the efficacy and safety of temsirolimus and bevacizumab combination. Both efficacy and safety were demonstrated as insufficient. Interestingly, 2 control arms were used in this study, sunitinib (arm B) or bevacizumab and a-interferon (arm C). Both PFS and RR were higher in arm C than arm B (16.8 mths and 39% vs. 8.6 mths and 23.8%). Post-hoc analysis were thus performed to determine the predictive factors for better efficacy. Methods: Overall, 171 pts were randomized in this study, 42 in arm B and 41 in arm C. The study was stratified on PS only, 0–1 vs 2. These 83 pts were analyzed regarding baseline characteristics, and dose reduction. Results: Some important differences were detected in the 2 arms, in favor of arm C: DFI&gt;12mths (29 vs. 39%), good MSKCC risk (31 vs. 39%), Fuhrman grade 1–2 (32 vs. 38%), liver metastases (19 vs. 14.6%), high LDH (17.1 vs. 7.9%). Interestingly, pts who had dose reduction of interferon (27/41 pts) had a longer PFS than those who did not reduced the dose. Updated analyses will be presented. Conclusions: Small randomized trials such as randomized phase II trials are not guaranteed to balance predictive/ prognostic factors across treatment arms. Before interpreting RR and PFS in mRCC, careful analysis of pt characteristics should be performed. However, this study will probably help to determine a population more likely to benefit from bevacizumab-interferon combination. [Table: see text]
ECF chemotherapy for liver metastases due to castration-resistant prostate cancer (mCRPC).
Authors: S. Gupta, K. R. Potvin, F. Whiston, E. Winquist
Journal: Journal of Clinical Oncology (2011)

175 Background: Although 45% of mCRPC patients (pts) achieve prostatic-specific antigen (PSA) response with docetaxel, the objective response rate (ORR) is only 12% (Tannock 2004). Liver metastatic CRPC is uncommon and associated with shorter survival (Armstrong 2010). More active treatment might benefit these pts. ECF is highly active in gastric cancer (Findlay 1994) and response was reported in 3 of 5 liver mCRPC pts (Chao 1997). ECF has been used selectively for mCRPC pts at our centre and we retrospectively reviewed our results in pts with liver metastases with the primary objective of determining its antitumor activity. Methods: Patients with mCRPC who received ECF were identified from electronic databases. ECF (epirubicin 50 mg/m 2 IV day 1, cisplatin 60 mg/m 2 IV day 1 and fluorouracil 200 mg/m 2 IV daily as a continuous infusion) q21d was given as per Findlay et al. Patient, tumor, treatment and outcome data were extracted from medical records. Results: 14 mCRPC pts were treated with ECF 1996-2010. 7 pts had liver metastases: median age 57 years (42-76), median PSA 320 μg/L (17-494) and ECOG PS 1:2 (6:1). All 7 pts had multiple other poor prognostic features: pain (6), &gt;2 metastatic sites (6), anemia (6), ALP &gt;200 IU/L (6) and less than 3 years from diagnosis (6). A median 6 cycles (4-10) of ECF were administered. PSA dropped &gt; 50% for &gt; 4 weeks in 5 pts (71%) with a PSA drop &gt;90% in 4 pts. The ORR was 57% (95%CI, 20-94%) with 4 PR, 1 SD and 2 PD. Response was associated with improved symptoms and hepatic function. Adverse effects were similar to previous reports. Median PFS was 5.2 months (1.3-7.8+) and median overall survival 7.4 months (3.8-31.9). Pooling ORR data with that of Chao et al suggested a higher ORR than expected with docetaxel (58% vs 12%, p=0.03 Fisher's exact test). Conclusions: ECF was highly active in this small selected group of younger men with liver mCRPC and multiple poor prognostic features, and may be of interest for further study as a therapeutic alternative to docetaxel in mCRPC pts with liver metastases when prompt tumor shrinkage is necessary. No significant financial relationships to disclose.
Association of Sensory Processing With Higher-Order Cognition and Functioning in Schizophrenia
Authors: Sophia Vinogradov, Srikantan Nagarajan
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Dosimetic parameter predicting the hepatic complication after helical tomotherapy for patients with unresectable primary hepatocellular carcinoma.
Authors: HongSeok Jang
Journal: Journal of Clinical Oncology (2012)

324 Background: We evaluated the parameters of radiation-induced liver disease (RILD) and deterioration of the hepatic function in patients with advanced hepatocellular carcinoma (HCC), who were treated with helical tomotherapy. Methods: From April 2009 to October 2010, 32 patients with unresectable primary HCC received hypofractionated radiation therapy using the TomoTherapy Hi-Art (TomoTherapy, Madison, WI, USA) at Seoul St. Mary's Hospital, the Catholic University of Korea. To assess the deterioration of hepatic function, we evaluated the Child-Pugh class (CP class). The gross tumor volume (GTV) were 178.7 ± 216.1 cm 3 and the planning target volume (PTV) were 423.1 ± 399.7 cm 3 . The total dose administered were 50 Gy (range: 32.5-60 Gy) in 10 or 20 fractions (range: 10-24 fractions). We evaluated the clinical parameters for predicting the RILD and the deterioration of the hepatic function (gender, age, ECOG performance saretatus, pretreatment CP class, AJCC stage, pretreatment level of AFP and hepatitis, liver cirrhosis, PVTT and previous treatments) and the dosimetric parameters (GTV, PTV, the non-target liver volume (NTLV). Results: Of 32 patients, we observed that 4 patients (13%) developed RILD after helical tomotherapy. Classical RILD was diagnosed in one patient and non-classical RILD in three patients. In the analysis evaluating the associations between the clinical/dosimetric parameters and the RILD, there was no statistically significant parameter. Of 32 patients, five patients (16%) developed the progression of CP class. In the multivariate logistic regression analysis evaluating the associations between the clinical/dosimetric parameters and the progression of CP class, The NTLV receiving &lt;35 Gy (V BED35 ) was the only significant parameter associated with the risk of progression of CP class (p = 0.039). Conclusions: The progression of CP class is a dose-limiting toxicity. V BED35 was a significant parameter predicting the risk of the progression of CP class.
Multiethnic genome-wide meta-analysis of ectopic fat depots identifies loci associated with adipocyte development and differentiation
Authors: Audrey Y Chu, Xuan Deng, Virginia A Fisher, Alexander Drong, Yang Zhang, Mary F Feitosa, Ching-Ti Liu, Olivia Weeks, Audrey C Choh, Qing Duan, Thomas D Dyer, John D Eicher, Xiuqing Guo, Nancy L Heard-Costa, Tim Kacprowski, Jack W Kent, Leslie A Lange, Xinggang Liu, Kurt Lohman, Lingyi Lu, Anubha Mahajan, Jeffrey R O'Connell, Ankita Parihar, Juan M Peralta, Albert V Smith, Yi Zhang, Georg Homuth, Ahmed H Kissebah, Joel Kullberg, René Laqua, Lenore J Launer, Matthias Nauck, Michael Olivier, Patricia A Peyser, James G Terry, Mary K Wojczynski, Jie Yao, Lawrence F Bielak, John Blangero, Ingrid B Borecki, Donald W Bowden, John Jeffrey Carr, Stefan A Czerwinski, Jingzhong Ding, Nele Friedrich, Vilmunder Gudnason, Tamara B Harris, Erik Ingelsson, Andrew D Johnson, Sharon L R Kardia, Carl D Langefeld, Lars Lind, Yongmei Liu, Braxton D Mitchell, Andrew P Morris, Thomas H Mosley, Jerome I Rotter, Alan R Shuldiner, Bradford Towne, Henry Völzke, Henri Wallaschofski, James G Wilson, Matthew Allison, Cecilia M Lindgren, Wolfram Goessling, L Adrienne Cupples, Matthew L Steinhauser, Caroline S Fox
Journal: Nature Genetics (2016)
E-Cigarette Use Among Youth and Young Adults
Authors: Vivek H. Murthy
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal